FindTrial
Sign In

Cabotegravir (CAB) tablet

DRUG3 trials

Sponsors

ViiV Healthcare, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

HIV InfectionsInfection, Human Immunodeficiency Virus

Phase 2

Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males
CompletedNCT04692077
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
Start: 2020-02-19End: 2023-07-07Updated: 2025-05-20

Phase 3

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants
Active, not recruitingNCT02938520
ViiV HealthcareHIV Infections
Start: 2016-10-27End: 2029-12-31Updated: 2026-03-19
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
Active, not recruitingNCT02951052
ViiV HealthcareHIV Infections, Infection, Human Immunodeficiency Virus
Start: 2016-10-28End: 2029-12-31Updated: 2025-12-31

Related Papers

Subcutaneous injections of cabotegravir plus rilpivirine long-acting in virally suppressed adults with HIV-1.
2025-10-211 citations
Advances in HIV Treatment and Vaccine Development: Emerging Therapies and Breakthrough Strategies for Long-Term Control.
2025-07-041 citations
Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine Trials.
2024-07-0111 citations
Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP
Antimicrobial Agents and Chemotherapy2024-05-067 citations
Asian participants' experience in phase 3/3b studies of long‐acting cabotegravir and rilpivirine: Efficacy, safety, pharmacokinetic, and virological outcomes through week 96
HIV Medicine2023-12-261 citations
Psychometric Validation of the Perception of Injection (PIN) Questionnaire Using Data From Two Phase III, Open-Label, Active-Controlled, Non-Inferiority Studies in People Living With HIV.
2023-09-304 citations
Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain.
2023-07-1410 citations
Human Immunodeficiency Virus Type 1 RNA Levels in Rectal and Seminal Compartments After Switching to Long-Acting Cabotegravir Plus Rilpivirine: A Longitudinal Study
Clinical Infectious Diseases2022-08-202 citations
Indirect comparison of 48-week efficacy and safety of long-acting cabotegravir and rilpivirine maintenance every 8 weeks with daily oral standard of care antiretroviral therapy in participants with virologically suppressed HIV-1-infection.
2022-05-042 citations
Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.
2022-04-01401 citations
Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the <i>In Vitro</i> Potency of Cabotegravir or Rilpivirine.
2022-01-0318 citations
833. Efficacy and Safety of Long-Acting Cabotegravir + Rilpivirine in Participants with HIV/HCV Co-infection: ATLAS-2M 48-Week Results
Open Forum Infectious Diseases2021-11-01
875. Indirect Treatment Comparison of 48-Week Efficacy and Safety of Cabotegravir + Rilpivirine Long-Acting Every 2 Months to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Suppressed HIV-1 Infected Participants
Open Forum Infectious Diseases2021-11-01
Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study.
2021-10-14105 citations
Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy
AIDS2021-10-1334 citations
Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment
AIDS2021-07-1392 citations
Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).
2021-05-3156 citations
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.
2021-04-01137 citations
Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials
JAIDS Journal of Acquired Immune Deficiency Syndromes2020-08-21135 citations
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression
New England Journal of Medicine2020-03-04518 citations

4 more papers not shown